These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 12548584

  • 1. Antitumor effects of bisphosphonates.
    Green JR.
    Cancer; 2003 Feb 01; 97(3 Suppl):840-7. PubMed ID: 12548584
    [Abstract] [Full Text] [Related]

  • 2. Bisphosphonates: preclinical review.
    Green JR.
    Oncologist; 2004 Feb 01; 9 Suppl 4():3-13. PubMed ID: 15459425
    [Abstract] [Full Text] [Related]

  • 3. The antitumor potential of bisphosphonates.
    Clézardin P.
    Semin Oncol; 2002 Dec 01; 29(6 Suppl 21):33-42. PubMed ID: 12584693
    [Abstract] [Full Text] [Related]

  • 4. Bisphosphonates: the first 40 years.
    Russell RG.
    Bone; 2011 Jul 01; 49(1):2-19. PubMed ID: 21555003
    [Abstract] [Full Text] [Related]

  • 5. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ.
    J Bone Miner Res; 2000 Aug 01; 15(8):1467-76. PubMed ID: 10934645
    [Abstract] [Full Text] [Related]

  • 6. Bisphosphonates for the prevention of bone metastases.
    Coleman RE.
    Semin Oncol; 2002 Dec 01; 29(6 Suppl 21):43-9. PubMed ID: 12584694
    [Abstract] [Full Text] [Related]

  • 7. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H, Sohara Y, Moats RA, Nelson MD, Groshen SG, Ye W, Reynolds CP, DeClerck YA.
    Cancer Res; 2007 Oct 01; 67(19):9346-55. PubMed ID: 17909043
    [Abstract] [Full Text] [Related]

  • 8. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
    Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW.
    J Urol; 2003 Jul 01; 170(1):246-52. PubMed ID: 12796698
    [Abstract] [Full Text] [Related]

  • 9. Antitumor effects of bisphosphonates: promising preclinical evidence.
    Guise TA.
    Cancer Treat Rev; 2008 Jul 01; 34 Suppl 1():S19-24. PubMed ID: 18486348
    [Abstract] [Full Text] [Related]

  • 10. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
    Kellinsalmi M, Mönkkönen H, Mönkkönen J, Leskelä HV, Parikka V, Hämäläinen M, Lehenkari P.
    Basic Clin Pharmacol Toxicol; 2005 Dec 01; 97(6):382-91. PubMed ID: 16364054
    [Abstract] [Full Text] [Related]

  • 11. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention.
    Lipton A.
    J Support Oncol; 2004 Dec 01; 2(3):205-13; discussion 213-4, 216-7, 219-20. PubMed ID: 15328823
    [Abstract] [Full Text] [Related]

  • 12. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ, Thompson K, Gordon S, Rogers MJ.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [Abstract] [Full Text] [Related]

  • 13. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.
    Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF.
    J Bone Miner Res; 1995 Oct 15; 10(10):1478-87. PubMed ID: 8686503
    [Abstract] [Full Text] [Related]

  • 14. Preclinical pharmacology of zoledronic acid.
    Green JR.
    Semin Oncol; 2002 Dec 15; 29(6 Suppl 21):3-11. PubMed ID: 12584689
    [Abstract] [Full Text] [Related]

  • 15. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
    Fournier PG, Daubiné F, Lundy MW, Rogers MJ, Ebetino FH, Clézardin P.
    Cancer Res; 2008 Nov 01; 68(21):8945-53. PubMed ID: 18974139
    [Abstract] [Full Text] [Related]

  • 16. Anti-tumor potential of bisphosphonates.
    Green JR.
    Med Klin (Munich); 2000 Oct 15; 95 Suppl 2():23-8. PubMed ID: 11089384
    [Abstract] [Full Text] [Related]

  • 17. The backbone of progress--preclinical studies and innovations with zoledronic acid.
    Green JR, Guenther A.
    Crit Rev Oncol Hematol; 2011 Feb 15; 77 Suppl 1():S3-S12. PubMed ID: 21353178
    [Abstract] [Full Text] [Related]

  • 18. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
    Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH.
    Calcif Tissue Int; 2008 Mar 15; 82(3):191-201. PubMed ID: 18259679
    [Abstract] [Full Text] [Related]

  • 19. Bisphosphonates: from bench to bedside.
    Russell RG.
    Ann N Y Acad Sci; 2006 Apr 15; 1068():367-401. PubMed ID: 16831938
    [Abstract] [Full Text] [Related]

  • 20. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.
    Dumon JC, Journé F, Kheddoumi N, Lagneaux L, Body JJ.
    Eur Urol; 2004 Apr 15; 45(4):521-8; discussion 528-9. PubMed ID: 15041119
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.